Clinical Trial

A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of HSK31679 compared to placebo in patients with metabolic dysfunction-associated steatohepatitis (MASH) .
Protocol Amendment History 2 changes
critical Primary endpoint(s) modified 2026-06-18
minor Completion pushed: 2029-08-30 -> 2032-12-30 2026-06-18
Trial Details
NCT Number NCT07581951
Lead Sponsor Haisco Pharmaceutical Group Co., Ltd.
Conditions MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH (Non-Alcoholic Steatohepatitis)
Enrollment 400 participants
Start Date 2026-06-30
Primary Completion 2029-06-30 (estimated)
Study Completion 2032-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-17